SNDX Syndax Pharmaceuticals Inc Insider Trading

SNDX CEO Michael Metzger sold 32.4K shares at $24.24 via scheduled 10b5-1 plan; holds 484.8K post-sale

CEO Michael A Metzger executed a scheduled sale of 32,375 shares at $24.24 on 2026-07-08 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 517.2K to 484.8K shares (-6.3%). The transaction was automatic, not discretionary, eliminating timing as a factor for interpretation. Syndax is unprofitable (net income of -$42.7M in the latest quarter) with a $2.2B market cap, though it posted robust annual revenue growth of +627.8%. The stock has appreciated 40.4% over the past 30 days and trades at 2.9% below its 52-week high of $25.59. The sale occurred under a locked-in schedule, so it reflects neither conviction nor concern about current valuation or near-term prospects.

Syndax Pharmaceuticals R&D head sells 65,515 shares for $1.2M under 10b5-1 plan as stock falls 22.3% in 90 days

Nicholas A.J. Botwood, Head of R&D and CMO at Syndax, executed 2 separate sales totaling 65,515 shares for $1,183,642.90 at blended average price $18.07 on 2026-06-11 and 2026-06-12. This sale represents a 51.8% reduction in his pre-transaction holdings of 126,400 shares, leaving him with 60,885 shares post-transaction. The sales were scheduled under a 10b5-1 trading plan rather than discretionary decisions. Against the current price of $18.25, the stock is down 22.3% over the prior 90 days and down 28.7% from its 52-week high of $25.59. The company remains unprofitable with net income of $-42,673,000.00 in the latest quarter, despite significant revenue growth of 627.8% year-over-year to $64,864,000.00. His prior purchase at this same ticker on 2025-05-16 showed 90-day returns of 63.8%, but his current planned sales occur amid material stock weakness and ongoing operational losses.

CEO Michael A Metzger sold 157,307 shares of SNDX at $16.41 on 2025-09-08 ($2.6M) via pre-arranged 10b5-1 plan

CEO Michael A Metzger executed a scheduled sale of 157,307 shares under a pre-arranged 10b5-1 trading plan adopted on 2025-09-10, reducing his holdings by 34.5% from 455,968 to 298,661 shares. The sale proceeds totaled $2,582,021.37 at $16.41 per share. Because this transaction is part of a pre-established trading plan rather than discretionary trading, the timing and price reflect the automatic execution schedule, not current market judgment. The significant reduction in insider holdings warrants investor monitoring to understand whether prior planned diversification, compensation structure changes, or other corporate factors drove the plan's adoption.

Director Keith Katkin bought 10,000 shares of SNDX at $9.11; 3 other insiders bought within 14 days amid -62.5% from 52-week high.

Director Keith Katkin purchased 10,000 shares at $9.11 on 2025-05-19, increasing his holdings by 11.1% to 100,000 shares total. This purchase occurs within a cluster pattern: 3 other insiders also bought within the past 14 days. The stock is trading at $9.30, down 62.5% from its 52-week high of $24.81 and down 36.4% over the past 90 days. The company reported revenue of $20,042,000.00 in its latest quarter but is unprofitable with a net loss of $84,846,000.00 over its most recent fiscal year. The coordinated buying activity at a depressed price level, combined with the company's significant losses, warrants examination of whether insiders perceive the current valuation as disconnected from near-term operational performance, or whether additional strategic context is driving the transactions.

CFO Keith Goldan buys 3,000 shares of SNDX; cluster pattern with 3 other insiders buying within 14 days as stock down 62.5% from 52-week high

Keith Goldan, CFO of Syndax Pharmaceuticals, purchased 3,000 shares at an unspecified price on 2025-05-19, bringing his holdings to 93,746 shares. This transaction occurs in a cluster context: 3 other insiders also bought within the past 14 days, suggesting coordinated or near-simultaneous accumulation. The stock is currently trading at $9.30, down 62.5% from its 52-week high of $24.81, and down 19.4% over the past 30 days. Against this backdrop of sustained decline, the company reported $20.0M in quarterly revenue against a net loss of $84.8M, highlighting operational unprofitability. Goldan's own prior buy at this ticker on 2024-06-14 generated a 90-day return of -10.2%, showing that his previous accumulation in SNDX did not precede a recovery; the current multi-insider buy pattern occurs as the stock remains materially impaired from its peak.

Head of R&D at unprofitable SNDX buys 11,765 shares ($105.8K) at $9.00; 3 other insiders also bought in past 14 days.

Botwood Nicholas A.J., Head of R&D and CMO, purchased 11,765 shares for $105,826.18, expanding his holdings by 50.3% to 35,165 shares total. The transaction occurs amid significant price weakness: the stock trades at $9.30, down 62.5% from its 52-week high of $24.81 and down 19.4% over the past 30 days. Critically, the company reported net income of $-84,846,000.00 on revenue of $20,042,000.00, reflecting material unprofitability. The cluster signal—three other insiders also purchasing within the past 14 days—indicates coordinated accumulation by the insider group despite operational losses and depressed equity valuation. This pattern is worth monitoring to determine whether it reflects confidence in an inflection point or simply takes advantage of depressed pricing.

Director Martin H. Huber Jr. buys 5,000 SNDX shares at $8.99; 3 other insiders also bought within 14 days amid -36.4% 90-day decline.

Director Martin H. Huber Jr. purchased 5,000 shares at $8.99 on 2025-05-19, increasing his holdings to 79,000 shares from 74,000 shares. This transaction occurs within a broader insider buying cluster: 3 other insiders also purchased shares within the past 14 days. Notably, this activity unfolds against a backdrop of significant price deterioration—the stock has declined 36.4% over the past 90 days and is -62.5% from its 52-week high of $24.81. The company remains unprofitable with a net loss of $84,846,000.00 against quarterly revenue of $20,042,000.00, making the timing and magnitude of this coordinated buying pattern noteworthy for understanding insider sentiment relative to current valuation and operational performance.

CFO Keith A. Goldan buys 1,250 shares of SNDX at $20.03 amid negative fundamentals and recent price weakness.

Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals, purchased 1,250 shares at $20.03 on 2024-06-14, adding to a holding of 52.6K shares post-transaction. The purchase occurred as the stock trades at $19.88, down 19.1% from its 52-week high and 2.0% below its 30-day average. The company reported $12.4M in latest-quarter revenue but posted a $-72.4M net loss, with the full fiscal year also unprofitable. The modest purchase size relative to holdings (2.4% increase) and the stock's recent downward trajectory merit investor attention to the company's fundamental trajectory and whether this represents meaningful insider conviction or routine activity.